Sudheer Kumar Katari
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Sudheer Kumar Katari has a total of 68 co-authors. Here are the top co-authors by number of shared publications:
- Amineni Umamaheswari
Bioinformatics Centre, Department of Bioinformatics, SVIMS University, Tirupati, India
12 shared publications Chiranjeevi Pasala
Bioinformatics Centre, Department of Bioinformatics, SVIMS University, Tirupati, India
6 shared publications- Hemantha Mani Kumar Chakravarthi Chanda
Department of Bioinformatics, Vignan's Foundation for Science, Technology and Research (Deemed to be University),Vadlamudi, Guntur, 522213, India
5 shared publications Ravina Madhulitha Nalamolu
Bioinformatics Centre, Department of Bioinformatics, SVIMS University, Tirupati, 517507, AP, India
5 shared publicationsAnil Kumar Singh
4 shared publicationsAparna R. Bitla
Department of Biochemistry, SVIMS University, Tirupati, 517507, AP, India
4 shared publications
Latest Publications
- 23 September 2026
- Published by Bentham Science Publishers Ltd. in Current Computer-Aided Drug Design
- Vol. 22, 1-31
Identification of Novel Tubulin Dimer Inhibitors for Pancreatic Cancer Using an Integrated Computational Approach
Introduction: Pancreatic cancer remains one of the most aggressive and fatal malignancies, with survival rates below 10% due to late-stage diagnosis and resistance to conventional therapies. Disruption of microtubule dynamics by targeting the α-β tubulin dimer represents a promising therapeutic strategy. This study aims to identify novel tubulin dimer inhibitors using an integrated computational drug discovery approach. materials and methods: A comprehensive in silico workflow was employed, combining molecular docking, density functional theory (DFT), molecular dynamics (MD) simulations, and principal component analysis (PCA). DrugBank compounds were screened to identify candidates with high binding affinity to the tubulin dimer. DFT calculations were performed to analyze electronic interactions, while MD simulations (1 µs) assessed complex stability and conformational dynamics. PCA was used to evaluate protein-ligand flexibility and adaptability. results: Bisphosphonate-8 and Fenoldopam were identified as potential inhibitors, with Paclitaxel used as a reference compound. Docking and binding free energy analysis revealed that Bisphosphonate-8 demonstrated nearly 2-fold higher binding affinity compared to Paclitaxel. DFT calculations confirmed strong interaction potential. MD simulations showed that Bisphosphonate-8 formed a stable complex with the tubulin dimer throughout the trajectory, while Paclitaxel exhibited significant instability. PCA confirmed the conformational adaptability and dynamic stability of Bisphosphonate-8. discussion: The integrated computational approach effectively identified Bisphosphonate-8 as a novel tubulin dimer inhibitor with enhanced binding efficiency, superior stability, and favorable pharmacokinetic predictions. Compared to known microtubule-targeting agents, Bisphosphonate-8 showed improved interaction and adaptability, supporting its potential as a lead compound for further investigation. conclusion: This study provides strong in silico evidence supporting Bisphosphonate-8 as a promising candidate for targeting the α-β tubulin dimer in pancreatic cancer. While findings are predictive and require experimental validation, the data offer a valuable foundation for future biochemical and preclinical studies aimed at developing targeted therapies for pancreatic cancer.
- 23 September 2026
- Published by Bentham Science Publishers Ltd. in Current Computer-Aided Drug Design
- Vol. 22, 1-31
Identification of Novel Tubulin Dimer Inhibitors for Pancreatic Cancer Using an Integrated Computational Approach
Introduction: Pancreatic cancer remains one of the most aggressive and fatal malignancies, with survival rates below 10% due to late-stage diagnosis and resistance to conventional therapies. Disruption of microtubule dynamics by targeting the α-β tubulin dimer represents a promising therapeutic strategy. This study aims to identify novel tubulin dimer inhibitors using an integrated computational drug discovery approach. materials and methods: A comprehensive in silico workflow was employed, combining molecular docking, density functional theory (DFT), molecular dynamics (MD) simulations, and principal component analysis (PCA). DrugBank compounds were screened to identify candidates with high binding affinity to the tubulin dimer. DFT calculations were performed to analyze electronic interactions, while MD simulations (1 µs) assessed complex stability and conformational dynamics. PCA was used to evaluate protein-ligand flexibility and adaptability. results: Bisphosphonate-8 and Fenoldopam were identified as potential inhibitors, with Paclitaxel used as a reference compound. Docking and binding free energy analysis revealed that Bisphosphonate-8 demonstrated nearly 2-fold higher binding affinity compared to Paclitaxel. DFT calculations confirmed strong interaction potential. MD simulations showed that Bisphosphonate-8 formed a stable complex with the tubulin dimer throughout the trajectory, while Paclitaxel exhibited significant instability. PCA confirmed the conformational adaptability and dynamic stability of Bisphosphonate-8. discussion: The integrated computational approach effectively identified Bisphosphonate-8 as a novel tubulin dimer inhibitor with enhanced binding efficiency, superior stability, and favorable pharmacokinetic predictions. Compared to known microtubule-targeting agents, Bisphosphonate-8 showed improved interaction and adaptability, supporting its potential as a lead compound for further investigation. conclusion: This study provides strong in silico evidence supporting Bisphosphonate-8 as a promising candidate for targeting the α-β tubulin dimer in pancreatic cancer. While findings are predictive and require experimental validation, the data offer a valuable foundation for future biochemical and preclinical studies aimed at developing targeted therapies for pancreatic cancer.
- 26 April 2026
- Published by Springer Nature in Molecular Diversity
- Vol. 30 (5) , 8061-8085
In silico discovery of natural and synthetic inhibitors targeting AKT1 in prostate cancer
- 26 April 2026
- Published by Springer Nature in Molecular Diversity
- Vol. 30 (5) , 8061-8085
In silico discovery of natural and synthetic inhibitors targeting AKT1 in prostate cancer
- 7 April 2026
- Published by Bentham Science Publishers Ltd. in Current Drug Discovery Technologies
- Vol. 23
Targeting TMPRSS2 for Prostate Cancer Therapy: A Multi-Step Computational Approach for Identifying Novel Inhibitors
Introduction: Prostate cancer is one of the most prevalent death-causing diseases among males, and metastatic progression leads to significant mortality. The transmembrane serine protease 2 (TMPRSS2) is often overexpressed or fused with the ETS-related gene (ERG) in prostate cancer patients. These molecular alterations play a pivotal role in tumour progression and metastasis. This integrated computational drug repurposing approach aimed to identify and characterize potential TMPRSS2 inhibitors among Food and Drug Administra-tion (FDA) approved compounds. Given the exclusively in silico nature of this work, the find-ings should be interpreted as preliminary. Methods: A high-throughput molecular docking screening was conducted using FDA-ap-proved compounds from DrugBank against the TMPRSS2 catalytic domain (active site). Top-scoring ligands were further analysed through pharmacokinetic profiling. Likewise, 1 μs mo-lecular dynamics simulations (MDS) were performed within a lipid bilayer environment. Sta-bility and interaction strength were evaluated through root mean square deviation (RMSD), hydrogen bonding, and radius of gyration (rGyr). Moreover, solvent-accessible surface area (SASA), polar surface area (PSA), cluster analysis, and principal component analysis (PCA) were also used for evaluation. Results: Through high binding affinities and stable interactions of drugs, Iotrolan, Iodixanol, and Hyaluronate emerged as top candidates. The Iotrolan-TMPRSS2 complex demonstrated the greatest stability, with an average protein RMSD of 2.44 Å. Likewise 6,988 hydrogen bonds, and 9,100 water-bridge formations contributed to the stability of Iotrolan-TMPRSS2 complex. Structural metrics (rGyr, SASA, PSA) indicated compact and stable ligand confor-mations throughout the simulation. Clustering analysis showed that over 60% of simulation frames for Iotrolan localized within five dominant conformational clusters. PCA revealed that the first three eigenvectors accounted for 63% of the total motion, suggesting ligand-induced modulation of TMPRSS2 dynamics. Discussion: Iotrolan stabilizes the protein structure and restricts its conformational flexibility exhibited strong and persistent interactions with TMPRSS2, which suggests a stronger inhib-itory potential compared to in silico. Iodixanol showed moderate stabilization with fewer per-sistent contacts. Hyaluronate displayed internal ligand stability but induced higher protein flexibility, potentially reducing inhibitory efficacy. Despite promising interactions, poor oral bioavailability and membrane permeability highlight the need for optimization and further ex-perimental evaluation. Conclusion: This multi-step combinational computational analysis identifies Iotrolan as a pre-liminary and promising candidate for further investigation as a TMPRSS2 inhibitor. These findings represent preliminary computational predictions only and should be interpreted with caution. They require rigorous in vitro and in vivo validation before any biological or thera-peutic relevance can be established. This work provides a structural framework that may guide future experimental studies in TMPRSS2-targeted drug discovery.
- 7 April 2026
- Published by Bentham Science Publishers Ltd. in Current Drug Discovery Technologies
- Vol. 23
Targeting TMPRSS2 for Prostate Cancer Therapy: A Multi-Step Computational Approach for Identifying Novel Inhibitors
Introduction: Prostate cancer is one of the most prevalent death-causing diseases among males, and metastatic progression leads to significant mortality. The transmembrane serine protease 2 (TMPRSS2) is often overexpressed or fused with the ETS-related gene (ERG) in prostate cancer patients. These molecular alterations play a pivotal role in tumour progression and metastasis. This integrated computational drug repurposing approach aimed to identify and characterize potential TMPRSS2 inhibitors among Food and Drug Administra-tion (FDA) approved compounds. Given the exclusively in silico nature of this work, the find-ings should be interpreted as preliminary. Methods: A high-throughput molecular docking screening was conducted using FDA-ap-proved compounds from DrugBank against the TMPRSS2 catalytic domain (active site). Top-scoring ligands were further analysed through pharmacokinetic profiling. Likewise, 1 μs mo-lecular dynamics simulations (MDS) were performed within a lipid bilayer environment. Sta-bility and interaction strength were evaluated through root mean square deviation (RMSD), hydrogen bonding, and radius of gyration (rGyr). Moreover, solvent-accessible surface area (SASA), polar surface area (PSA), cluster analysis, and principal component analysis (PCA) were also used for evaluation. Results: Through high binding affinities and stable interactions of drugs, Iotrolan, Iodixanol, and Hyaluronate emerged as top candidates. The Iotrolan-TMPRSS2 complex demonstrated the greatest stability, with an average protein RMSD of 2.44 Å. Likewise 6,988 hydrogen bonds, and 9,100 water-bridge formations contributed to the stability of Iotrolan-TMPRSS2 complex. Structural metrics (rGyr, SASA, PSA) indicated compact and stable ligand confor-mations throughout the simulation. Clustering analysis showed that over 60% of simulation frames for Iotrolan localized within five dominant conformational clusters. PCA revealed that the first three eigenvectors accounted for 63% of the total motion, suggesting ligand-induced modulation of TMPRSS2 dynamics. Discussion: Iotrolan stabilizes the protein structure and restricts its conformational flexibility exhibited strong and persistent interactions with TMPRSS2, which suggests a stronger inhib-itory potential compared to in silico. Iodixanol showed moderate stabilization with fewer per-sistent contacts. Hyaluronate displayed internal ligand stability but induced higher protein flexibility, potentially reducing inhibitory efficacy. Despite promising interactions, poor oral bioavailability and membrane permeability highlight the need for optimization and further ex-perimental evaluation. Conclusion: This multi-step combinational computational analysis identifies Iotrolan as a pre-liminary and promising candidate for further investigation as a TMPRSS2 inhibitor. These findings represent preliminary computational predictions only and should be interpreted with caution. They require rigorous in vitro and in vivo validation before any biological or thera-peutic relevance can be established. This work provides a structural framework that may guide future experimental studies in TMPRSS2-targeted drug discovery.
- Open Access
- 1 March 2026
- Published by Scifiniti Publishing in Molecular Modeling Connect
- Vol. 3 (1) , 1-10
Computational Exploration of Mutant SARS-CoV-2 Main Protease as a Target for Binding and Inhibition Attributes Utilizing Antiviral Drugs for Therapeutic Application
The main protease (Mpro) of SARS-CoV-2 signifies a significant focus for antiviral drug development, serving as a vital enzyme in the virus's life cycle. The inhibition of SARS-CoV-2 Mpro constitutes a promising approach for developing therapeutic agents intended for the treatment of SARS-CoV-2 and similar viruses. This study investigates the structural, functional, binding, and inhibition attributes of the SARS-CoV-2 Mpro by implementing protein flexibility modeling and docking with selected antiviral agents, including Acyclovir, Remdesivir, Sofosbuvir, Atazanavir, Cidofovir, Indinavir, Lopinavir, Oseltamivir, Galidesivir, and Favipiravir. Protein flexibility modeling revealed that the maximum fluctuation occurred at residue index 306, with an average RMSF value of 3.8 Å. The lowest binding affinity observed for the Mpro-Atazanavir complex was determined to be -8.1 Kcal/mol, corresponding to a Ki value of 5.95 µM. The docked lowest binding affinity was found for the common active site residues, including GLN-110, ASN-151, VAL-202, HIS-246, ILE-249, PRO-252, PHE-294, and VAL-297, which involve hydrogen bond interactions between the protein and ligands. Selected antiviral drugs exhibit adequate binding affinity and inhibitory effectiveness; hence, comparable chemical property compounds may be selected to repurpose viable therapeutic candidates as Mpro inhibitors.
- 1 March 2026
- Published by Scifiniti Publishing in Molecular Modeling Connect
- Vol. 3 (1) , 1-10
Open AccessComputational Exploration of Mutant SARS-CoV-2 Main Protease as a Target for Binding and Inhibition Attributes Utilizing Antiviral Drugs for Therapeutic Application
The main protease (Mpro) of SARS-CoV-2 signifies a significant focus for antiviral drug development, serving as a vital enzyme in the virus's life cycle. The inhibition of SARS-CoV-2 Mpro constitutes a promising approach for developing therapeutic agents intended for the treatment of SARS-CoV-2 and similar viruses. This study investigates the structural, functional, binding, and inhibition attributes of the SARS-CoV-2 Mpro by implementing protein flexibility modeling and docking with selected antiviral agents, including Acyclovir, Remdesivir, Sofosbuvir, Atazanavir, Cidofovir, Indinavir, Lopinavir, Oseltamivir, Galidesivir, and Favipiravir. Protein flexibility modeling revealed that the maximum fluctuation occurred at residue index 306, with an average RMSF value of 3.8 Å. The lowest binding affinity observed for the Mpro-Atazanavir complex was determined to be -8.1 Kcal/mol, corresponding to a Ki value of 5.95 µM. The docked lowest binding affinity was found for the common active site residues, including GLN-110, ASN-151, VAL-202, HIS-246, ILE-249, PRO-252, PHE-294, and VAL-297, which involve hydrogen bond interactions between the protein and ligands. Selected antiviral drugs exhibit adequate binding affinity and inhibitory effectiveness; hence, comparable chemical property compounds may be selected to repurpose viable therapeutic candidates as Mpro inhibitors.
- Open Access
- 1 March 2026
- Published by Scifiniti Publishing in Molecular Modeling Connect
- Vol. 3 (1) , 1-10
Computational Investigation of Selected Antivirals and mAbs Targeting the RBD of Omicron to Get Insights into Structure and Binding Attributes
Multiple mutations in SARS-CoV-2 (nCoV) have led to the emergence of VOCs. Mutations in the receptor- RBD can significantly influence viral interaction with cell surface receptors, alter pathogenicity, and facilitate immune evasion. Such VOCs pose a significant public health risk due to their ability to evade immune responses, as well as their altered pathogenicity and transmissibility. To address these challenges, we investigated the structure, function, and binding efficiency of the RBDs of VOCs using selected antiviral drugs and mAbs. The SSEs of the S protein of VOCs were found to comprise 26.79–29.43% α-helices (Hh), 21.64–22.37% extended strands (Ee), 3.54–5.12% β-turns (Tt), and 45.40–46.84% random coils (Cc). Docking simulations revealed that the nCoV-RBD-Lopinavir complex exhibited the lowest binding affinity (−8.8 ± 0.55 Kcal/mol), by forming hydrogen-bond interactions with ALA-27 and ALA-143 residues. Similarly, the Omicron RBD–Indinavir complex exhibited the lowest binding affinity (−7.4 ± 0.06 Kcal/mol), involving residues ARG355, ASP428, THR430, SER514, and GLU516 in hydrogen-bond interactions. Protein–protein docking of the Omicron RBD–ACE2 complex revealed a favorable docking score of −846.2, compared with the reference complex (−703.1). The findings presented herein highlight substantial structural and functional alterations in the Omicron RBD compared with the reference nCoV RBD. This variation showcases the diverse binding affinities of selected antiviral drugs and mAbs. These findings may pave the way for experimental validation and contribute to a deeper understanding of potential therapeutic options against SARS-CoV-2 and related diseases.
- 1 March 2026
- Published by Scifiniti Publishing in Molecular Modeling Connect
- Vol. 3 (1) , 1-10
Open AccessComputational Investigation of Selected Antivirals and mAbs Targeting the RBD of Omicron to Get Insights into Structure and Binding Attributes
Multiple mutations in SARS-CoV-2 (nCoV) have led to the emergence of VOCs. Mutations in the receptor- RBD can significantly influence viral interaction with cell surface receptors, alter pathogenicity, and facilitate immune evasion. Such VOCs pose a significant public health risk due to their ability to evade immune responses, as well as their altered pathogenicity and transmissibility. To address these challenges, we investigated the structure, function, and binding efficiency of the RBDs of VOCs using selected antiviral drugs and mAbs. The SSEs of the S protein of VOCs were found to comprise 26.79–29.43% α-helices (Hh), 21.64–22.37% extended strands (Ee), 3.54–5.12% β-turns (Tt), and 45.40–46.84% random coils (Cc). Docking simulations revealed that the nCoV-RBD-Lopinavir complex exhibited the lowest binding affinity (−8.8 ± 0.55 Kcal/mol), by forming hydrogen-bond interactions with ALA-27 and ALA-143 residues. Similarly, the Omicron RBD–Indinavir complex exhibited the lowest binding affinity (−7.4 ± 0.06 Kcal/mol), involving residues ARG355, ASP428, THR430, SER514, and GLU516 in hydrogen-bond interactions. Protein–protein docking of the Omicron RBD–ACE2 complex revealed a favorable docking score of −846.2, compared with the reference complex (−703.1). The findings presented herein highlight substantial structural and functional alterations in the Omicron RBD compared with the reference nCoV RBD. This variation showcases the diverse binding affinities of selected antiviral drugs and mAbs. These findings may pave the way for experimental validation and contribute to a deeper understanding of potential therapeutic options against SARS-CoV-2 and related diseases.
- 21 November 2025
- Published by Springer Nature in In Silico Pharmacology
- Vol. 13 (3) , 189
Decoding gout pathogenesis: target discovery and drug design through computational models
The study presents a comprehensive approach to target prediction for gout (DOID: 13189) through the integration of disease ontology and network-based strategies. A total of 13 proteins associated with gout were identified and analyzed using the STRING database, which visualized protein-protein interactions (PPIs). Cytoscape, enhanced with the CytoHubba plugin, was used to prioritize key proteins, identifying Solute loading carrier family 22 member 12 (SLC22A12) and SLC22A9 genes as the most promising targets based on their high degree of interaction. Sequence alignment of these proteins (Urate Anion Exchanger 1-URAT1 and Organic anion transporter 7-OAT7) revealed significant homology, suggesting that they play complementary roles in uric acid transport and gout pathogenesis. Molecular docking by AutoDock Vina and AutoDock4 of whole Indian Medicinal Plants, Phytochemistry And Therapeutics (IMPPAT) database, Food and Drug Administration (FDA) Approved Drugs revealed three leads from the Woodfordia fruticosa (Heterophylliin A), Arctium lappa (Arctignan D), and Oroxylum indicum (Scutellarein 7-rutinoside) demonstrated strong binding affinities with URAT1 through favorable docking interactions over the best docked Fostemsavir and URAT1 inhibitors (Lesinurad and Benzbromarone) indicating their potential as modulators of uric acid transport. The molecular dynamics simulations (MDS) of URAT1 in membrane environment with the identified compounds by Desmond further supported that all three leads exhibited superior binding stability, binding energy and interaction profiles compared to the existing drugs. The results highlight the potential of these phytochemicals upon further experimental validation as therapeutic agents for gout. This integrative bioinformatics and computational approach provide a robust framework for discovering potent drug target and bioactive compounds with strong potential for effective gout treatment if further validated through in vitro and in vivo assays. Graphical abstract
- 21 November 2025
- Published by Springer Nature in In Silico Pharmacology
- Vol. 13 (3) , 189
Decoding gout pathogenesis: target discovery and drug design through computational models
The study presents a comprehensive approach to target prediction for gout (DOID: 13189) through the integration of disease ontology and network-based strategies. A total of 13 proteins associated with gout were identified and analyzed using the STRING database, which visualized protein-protein interactions (PPIs). Cytoscape, enhanced with the CytoHubba plugin, was used to prioritize key proteins, identifying Solute loading carrier family 22 member 12 (SLC22A12) and SLC22A9 genes as the most promising targets based on their high degree of interaction. Sequence alignment of these proteins (Urate Anion Exchanger 1-URAT1 and Organic anion transporter 7-OAT7) revealed significant homology, suggesting that they play complementary roles in uric acid transport and gout pathogenesis. Molecular docking by AutoDock Vina and AutoDock4 of whole Indian Medicinal Plants, Phytochemistry And Therapeutics (IMPPAT) database, Food and Drug Administration (FDA) Approved Drugs revealed three leads from the Woodfordia fruticosa (Heterophylliin A), Arctium lappa (Arctignan D), and Oroxylum indicum (Scutellarein 7-rutinoside) demonstrated strong binding affinities with URAT1 through favorable docking interactions over the best docked Fostemsavir and URAT1 inhibitors (Lesinurad and Benzbromarone) indicating their potential as modulators of uric acid transport. The molecular dynamics simulations (MDS) of URAT1 in membrane environment with the identified compounds by Desmond further supported that all three leads exhibited superior binding stability, binding energy and interaction profiles compared to the existing drugs. The results highlight the potential of these phytochemicals upon further experimental validation as therapeutic agents for gout. This integrative bioinformatics and computational approach provide a robust framework for discovering potent drug target and bioactive compounds with strong potential for effective gout treatment if further validated through in vitro and in vivo assays. Graphical abstract
- Open Access
- 5 November 2025
- Published by Springer Nature in Research Square
Identification of Novel Tubulin Dimer Inhibitors for Pancreatic Cancer: An Integrated Computational Approach
Pancreatic cancer remains one of the most lethal malignancies, with mortality rates exceeding 90% in males and 89% in females, largely due to late-stage diagnosis and chemotherapy resistance. Despite advances in cancer research, effective treatment options for pancreatic cancer remain limited, highlighting the urgent need for novel therapeutic strategies. Identification of potent tubulin dimer inhibitors, disrupting the Alpha-Beta dimer complex essential for microtubule dynamics and cancer cell proliferation, offers a promising therapeutic avenue. Computational drug discovery provides an effective strategy to find novel inhibitors with enhanced binding efficiency, stability, and adaptability for personalized treatments. We implemented a multi-faceted computational approach combining molecular docking, density functional theory (DFT), molecular dynamics (MD) simulations, and principal component analysis (PCA). DrugBank screening identified Bisphosphonate-8 and Fenoldopam as potential inhibitors, with Paclitaxel as a reference drug. DFT calculations provided quantum mechanical insights into ligand-tubulin interactions, while binding energy analysis revealed Bisphosphonate-8 exhibiting a nearly 2-fold higher binding affinity than Paclitaxel. Microsecond-scale MD simulations assessed the stability and flexibility of ligand-protein complexes, and PCA analysis of MD simulations trajectories demonstrated significant conformational adaptability, reinforcing the potential of Bisphosphonate-8 and Fenoldopam as effective tubulin dimer inhibitors. Bisphosphonate-8, demonstrating superior binding properties in silico, emerges as a promising candidate for preclinical evaluation in pancreatic cancer, offering translational potential for improved targeted therapy.
- 5 November 2025
- Published by Springer Nature in Research Square
Open AccessIdentification of Novel Tubulin Dimer Inhibitors for Pancreatic Cancer: An Integrated Computational Approach
Pancreatic cancer remains one of the most lethal malignancies, with mortality rates exceeding 90% in males and 89% in females, largely due to late-stage diagnosis and chemotherapy resistance. Despite advances in cancer research, effective treatment options for pancreatic cancer remain limited, highlighting the urgent need for novel therapeutic strategies. Identification of potent tubulin dimer inhibitors, disrupting the Alpha-Beta dimer complex essential for microtubule dynamics and cancer cell proliferation, offers a promising therapeutic avenue. Computational drug discovery provides an effective strategy to find novel inhibitors with enhanced binding efficiency, stability, and adaptability for personalized treatments. We implemented a multi-faceted computational approach combining molecular docking, density functional theory (DFT), molecular dynamics (MD) simulations, and principal component analysis (PCA). DrugBank screening identified Bisphosphonate-8 and Fenoldopam as potential inhibitors, with Paclitaxel as a reference drug. DFT calculations provided quantum mechanical insights into ligand-tubulin interactions, while binding energy analysis revealed Bisphosphonate-8 exhibiting a nearly 2-fold higher binding affinity than Paclitaxel. Microsecond-scale MD simulations assessed the stability and flexibility of ligand-protein complexes, and PCA analysis of MD simulations trajectories demonstrated significant conformational adaptability, reinforcing the potential of Bisphosphonate-8 and Fenoldopam as effective tubulin dimer inhibitors. Bisphosphonate-8, demonstrating superior binding properties in silico, emerges as a promising candidate for preclinical evaluation in pancreatic cancer, offering translational potential for improved targeted therapy.
- 20 October 2025
- Published by Walter de Gruyter GmbH in Chemical Product and Process Modeling
- Vol. 21 (4) , 477-508
In Silico target identification and drug discovery for 5-proFAR isomerase inhibitors in critical fungal pathogens
Fungal infections, especially in immunocompromised individuals, are emerging as a significant global health threat, contributing to high morbidity and mortality rates. The growing resistance of pathogens like Cryptococcus neoformans , Aspergillus fumigatus , Candida albicans and Candida auris coupled with limited treatment options, underscores the urgent need for improved diagnostics and antifungal therapies. Utilizing a comprehensive comparative proteomic approach, we identified the critical role of 1-(5-phosphoribosyl)-5-[(5-phosphoribosylamino) methylideneamino] imidazole-4-carboxamide (5-proFAR) isomerase in Amino acid transport metabolism, a vital pathway for fungal growth and virulence. Through advanced in silico techniques, including molecular docking, molecular dynamics simulations (MDS), and Principal Component Analysis (PCA), we screened potential inhibitors and identified Mugineic acid and 9-amino-2-deoxy-2,3-dehydro-n-acetyl-neuraminate as the most promising candidates, displaying favorable binding affinity, stability, and strong interactions with key residues within the enzyme’s active site. These compounds exhibited low RMSD and RMSF values, indicative of high conformational stability, making them ideal candidates for further experimental validation. Our findings suggest that targeting 5-proFAR isomerase offers a broad-spectrum, resistance-evading therapeutic strategy that could significantly mitigate the global burden of fungal infections, particularly in immunocompromised individuals, thus paving the way for the development of next-generation antifungal drugs to combat the growing challenge of multidrug-resistant fungal pathogens.
- 20 October 2025
- Published by Walter de Gruyter GmbH in Chemical Product and Process Modeling
- Vol. 21 (4) , 477-508
In Silico target identification and drug discovery for 5-proFAR isomerase inhibitors in critical fungal pathogens
Fungal infections, especially in immunocompromised individuals, are emerging as a significant global health threat, contributing to high morbidity and mortality rates. The growing resistance of pathogens like Cryptococcus neoformans , Aspergillus fumigatus , Candida albicans and Candida auris coupled with limited treatment options, underscores the urgent need for improved diagnostics and antifungal therapies. Utilizing a comprehensive comparative proteomic approach, we identified the critical role of 1-(5-phosphoribosyl)-5-[(5-phosphoribosylamino) methylideneamino] imidazole-4-carboxamide (5-proFAR) isomerase in Amino acid transport metabolism, a vital pathway for fungal growth and virulence. Through advanced in silico techniques, including molecular docking, molecular dynamics simulations (MDS), and Principal Component Analysis (PCA), we screened potential inhibitors and identified Mugineic acid and 9-amino-2-deoxy-2,3-dehydro-n-acetyl-neuraminate as the most promising candidates, displaying favorable binding affinity, stability, and strong interactions with key residues within the enzyme’s active site. These compounds exhibited low RMSD and RMSF values, indicative of high conformational stability, making them ideal candidates for further experimental validation. Our findings suggest that targeting 5-proFAR isomerase offers a broad-spectrum, resistance-evading therapeutic strategy that could significantly mitigate the global burden of fungal infections, particularly in immunocompromised individuals, thus paving the way for the development of next-generation antifungal drugs to combat the growing challenge of multidrug-resistant fungal pathogens.
- Open Access
- 26 September 2025
- Published by Springer Nature in Research Square
In Silico Discovery of Natural and Synthetic Inhibitors Targeting AKT1 in Prostate Cancer
The serine/threonine kinase AKT1 plays a pivotal role in cancer progression and therapy resistance, particularly in castration-resistant prostate cancer (CRPC). This study employed an integrated in silico approach to identify potential AKT1 catalytic domain inhibitors from a library of 13,000 compounds sourced from Drugbank and the IMPPAT database. Structure-based virtual screening using AutoDock Vina and AutoDock 4.2 identified five promising candidates, among which 4-Carboxy imidazole and Balanol Analog 2 showed the most favourable binding interactions. Molecular dynamics (MD) simulations revealed that both compounds exhibited low RMSD and RMSF values, indicating stable binding throughout the simulation period. Notably, 4-Carboxy imidazole maintained persistent hydrogen bonding and low solvent exposure, suggesting a compact binding mode. Principal component analysis (PCA) and free energy landscape analyses further supported the conformational stability of these complexes. ADME profiling showed that 4-Carboxy imidazole had superior drug-like properties, while Balanol Analog 2 raised potential concerns related to metabolism. Density Functional Theory (DFT) calculations highlighted favourable electronic properties for both top ligands, with 4-Carboxy imidazole exhibiting a low dipole moment and moderate reactivity, suggesting specificity and stability. While the results are promising, further experimental validation is required to confirm inhibitory activity and therapeutic potential. Overall, this study identifies 4-Carboxy imidazole and Balanol Analog 2 as promising lead compounds for the development of AKT1-targeted therapies in CRPC.
- 26 September 2025
- Published by Springer Nature in Research Square
Open AccessIn Silico Discovery of Natural and Synthetic Inhibitors Targeting AKT1 in Prostate Cancer
The serine/threonine kinase AKT1 plays a pivotal role in cancer progression and therapy resistance, particularly in castration-resistant prostate cancer (CRPC). This study employed an integrated in silico approach to identify potential AKT1 catalytic domain inhibitors from a library of 13,000 compounds sourced from Drugbank and the IMPPAT database. Structure-based virtual screening using AutoDock Vina and AutoDock 4.2 identified five promising candidates, among which 4-Carboxy imidazole and Balanol Analog 2 showed the most favourable binding interactions. Molecular dynamics (MD) simulations revealed that both compounds exhibited low RMSD and RMSF values, indicating stable binding throughout the simulation period. Notably, 4-Carboxy imidazole maintained persistent hydrogen bonding and low solvent exposure, suggesting a compact binding mode. Principal component analysis (PCA) and free energy landscape analyses further supported the conformational stability of these complexes. ADME profiling showed that 4-Carboxy imidazole had superior drug-like properties, while Balanol Analog 2 raised potential concerns related to metabolism. Density Functional Theory (DFT) calculations highlighted favourable electronic properties for both top ligands, with 4-Carboxy imidazole exhibiting a low dipole moment and moderate reactivity, suggesting specificity and stability. While the results are promising, further experimental validation is required to confirm inhibitory activity and therapeutic potential. Overall, this study identifies 4-Carboxy imidazole and Balanol Analog 2 as promising lead compounds for the development of AKT1-targeted therapies in CRPC.